SCHEMBL6323293

SCHEMBL6323293

CC(S)CNS(=O)(=O)c1c(C(C)C)cc(C(C)C)cc1C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 4/20 0.50
FABP3 P05413 2/20 0.50
FABP5 Q01469 1/20 0.50
GAA P10253 1/20 0.44
HDAC1 Q13547 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
NR3C1 P04150 1/20 0.41
PDE4B Q07343 1/20 0.40
NPY5R Q15761 2/20 0.38
ALDH1A1 P00352 1/20 0.38
F10 P00742 1/20 0.36
ADAM17 P78536 1/20 0.35
GBA1 P04062 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
SOAT2 O75908 1/20 0.33
MYC P01106 1/20 0.33
SOAT1 P35610 1/20 0.33
MAP2K3 P46734 1/20 0.33
PLG P00747 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17115758 0.81 FABP4 (0.50) FABP4FABP3FABP5GAAHDAC1
SCHEMBL3684371 0.79 FABP4 (0.51) FABP4FABP3FABP5GAAHDAC1
SCHEMBL21922801 0.77 FABP4 (0.62) FABP4FABP3FABP5GAAHDAC1
SCHEMBL17611222 0.76 FABP3 (0.53) FABP4FABP3FABP5GAAHDAC1
SCHEMBL8602352 0.76 FABP4 (0.49) FABP4FABP3FABP5GAAHDAC1
SCHEMBL10452159 0.75 FABP4 (0.60) FABP4FABP3FABP5GAAHDAC1
SCHEMBL23052183 0.75 FABP4 (0.51) FABP4FABP3FABP5GAAHDAC1
SCHEMBL6323287 0.74 NR3C1 (0.52) FABP4FABP3FABP5GAAHDAC1
SCHEMBL6323291 0.74 NR3C1 (0.52) FABP4FABP3FABP5GAAHDAC1
SCHEMBL675038 0.74 FABP4 (0.58) FABP4FABP3FABP5GAAHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 FABP4 2333/4885FABP3 724/4885FABP5 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.